Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Solid Tumor 1Locally Advanced Unresectable Gastric Cancer 1Digestive System Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1

Interventions

Folfox protocol 3Drug Therapy 3Cisplatin 3apatinib 2anlotinib 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Capecitabine 2sintilimab 1pyrotinib 1pemigatinib 1huachansu 1donafenib 1Trastuzumab 1Sorafenib 1Radiotherapy 1Physical Conditioning, Human 1Microspheres 1Leucovorin 1Immune Checkpoint Inhibitors 1Docetaxel 1Chemoradiotherapy 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Digestive System Neoplasms × pemigatinib × Clear all
NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡